Self-organizing heart organoids developed at IMBA - Institute of Molecular Biotechnology of the Austrian Academy of Sciences - are also effective injury- and in vitro congenital disease models. These "cardioids" may revolutionize research into cardiovascular disorders and malformations of the heart. The results are published in the journal Cell.
About 18 million people die each year from cardiovascular diseases, making them the leading cause of fatalities globally. Moreover, the most prevalent birth defects in children pertain to the heart. Currently, a major bottleneck in understanding human heart malformations and developing regenerative therapies are missing human physiological models of the heart.
The research group of Sasha Mendjan established cardioids at IMBA - human self-organizing cardiac organoids that recapitulate the lineage architecture of a heart chamber. Mendjan explains: "Cardioids are a major milestone. Our guiding principle is that for an in vitro tissue to be fully physiological, it also needs to undergo organogenesis. We were able to achieve this, using the developmental principles of self-organization - which makes it such an exciting discovery".
During development, a heart chamber emerges from the mesoderm germ layer. The researchers thus established in vivo-like mesodermal signaling conditions guiding pluripotent stem cells. "Amazingly, this led to self-organization of a heart chamber-like structure that was beating. For the first time, we could observe something like this in a dish. It is a simple, robust and scalable model, and does not require addition of exogenous extracellular matrix like many other organoid models," explains Sasha Mendjan. Besides a beating myocardial layer, a functional heart also contains an inner endothelial lining that later contributes to heart vasculature, and an outer epicardial layer that directs heart growth and regeneration. Cardioids recapitulate this three layered structure, shaping a heart chamber-like structure.
The scientists determined how signaling and transcription factors control cardioid chamber formation. For instance, the team was able to phenocopy the dramatic chamber cavity loss observed in children with Hypoplastic Left Heart Syndrome in cardioids by disrupting a transcription factor linked to this defect. The researchers also assessed the effects of cryoinjury (injury by freezing), a technique mimicking myocardial infarction, on cardioids. For the first time in a dish, the team found that this injury triggers an in vivo-like accumulation of extracellular matrix proteins in cardioids, an early hallmark of both regeneration and fibrotic heart disease.
The self-organizing organoid field has revolutionized biomedical research over the past decade. However, the heart was the last major inner organ missing such a physiological model capable of recapitulating developmental and injury response processes. "Cardioids bear incredible potential to unravel human congenital heart defects. As the system is physiological and scalable, this opens up huge possibilities for drug discovery and regenerative medicine," says Sasha Mendjan.
This technology developed at IMBA has led to the creation of HeartBeat.bio, a new IMBA spin-off focused on the development of a high-throughput 3D screening platform for heart failure and cardiomyopathies. To the HeartBeat.bio website: https://heartbeat.bio/ .
Original publication: Hofbauer P, Jahnel SM, Papai N, et al., "Cardioids reveal self-organizing principles of human cardiogenesis", Cell, 2021. DOI: 10.1016/j.cell.2021.04.034 https://www.cell.com/cell/fulltext/S0092-8674(21)00537-7
IMBA - Institute of Molecular Biotechnology - is one of the leading biomedical research institutes in Europe focusing on cutting-edge stem cell technologies, functional genomics, and RNA biology. IMBA is located at the Vienna BioCenter, the vibrant cluster of universities, research institutes and biotech companies in Austria. IMBA is a subsidiary of the Austrian Academy of Sciences, the leading national sponsor of non-university academic research. The stem cell and organoid research at IMBA is being funded by the Austrian Federal Ministry of Science and the City of Vienna.